JPRN-jRCT2031220291招募中2 期
An early phase II study of RBM-007 in children with achondroplasia
onaka Yosuke0 个研究点目标入组 12 人开始时间: 2022年8月26日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 5age old 至 <= 14age old（—）
- 性别
- All
入选标准
- •(1) Able to obtain written informed consent from surrogate decision maker (parents, relatives or legal representative) before study entry
- •Able to obtain written informed assent from the patient after explaining the contents of this trial in the assent document (if possible)
- •(2) Has achondroplasia, diagnosed by genetic diagnosis
- •(3) Aged 5 to 14 years, inclusive, at study entry
- •(4) Able to lead a normal life without assistance
- •(5) Able to perform all the tests and administration of investigational product described in the protocol, judged by Investigator
- •(6) Participates in the observational study and has a height measurement record at the trial site at least 26 weeks (6 months) before study entry
排除标准
- •(1) Has short stature condition other than achondroplasia
- •(2) Has congenital diseases other than achondroplasia
- •(3) Has history of treatment with growth hormone or VOXZOGO within 38 weeks before study entry
- •(4) Has history of limb-lengthening surgery
- •(5) With a closed growth plate
- •(6) Has any of the following disorders that require surgical treatment on MRI or CT scans, or has clinically significant neurological symptoms or obstructive sleep apnea syndrome caused by these disorders: foramen magnum stenosis, spinal stenosis, hydrocephalus, spinal cord and cauda equina compression, etc (However, patients H146who have undergone surgical treatment for these disorders at least 52 weeks (12 months) before study entry and have no clinical problems can be enrolled)
- •(7) Has a history of allergies against the following products containing RBM-007 components (e.g., nucleic acid, polyethylene glycol, mannitol): prescribed medicines, vaccines, over-the-counter medicines, cosmetics, foods, etc
- •(8) Has history of cardiac or vascular disease
- •(9) Shows clinically significant abnormalities in the clinical laboratory test result, which is related to hepatic function or renal function before study entry
- •(10) Had a fracture of the long bones or spine within 52 weeks (12 months) before study entry (except for fracture of digits or toes)
- •(11) Has history of hip surgery, severe hip dysplasia or serious hip injury
- •(12) Highly likely to be unable to comply with RBM-007 treatment or to complete the trial, judged by the Investigator
- •(13) Used any other IP or investigational medical device within 52 weeks (12 months) before study entry
- •(14) Inadequate as a patient for this trial for any other reason than above, considered by the Investigator
研究者
相似试验
招募中
2 期
A long-term study of RBM-007 in children with achondroplasiaAchondroplasiaJPRN-jRCT2031220338onaka Yosuke12
进行中（未招募）
1 期
A phase I/II trial of ABTL0812 in children with relapsed/refractory neuroblastoma and other solid tumoursCTIS2023-504246-64-00Fir Huvh Fundacio Institut De Recerca Hospital Universitari Vall De Hebron48
进行中（未招募）
2 期
Phase 2 study of JR-142 in pediatric patients with growth hormone deficiencyGrowth hormone deficiency in childrenJPRN-jRCT2031200372Ryo Ibaraki24
已完成
2 期
A Multi-Center Phase II Study in Children with Newly Diagnosed Acute Promyelocytic Leukemia (APL)Acute promyelocytic leukemiaJPRN-UMIN000015348Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG)32
进行中（未招募）
1 期
Follow-Up study in Previously Treated Children to investigate a new FVIII concentrateEUCTR2011-001785-17-PLOctapharma AG50